Focus

Our research

What IMPACT is investigating

Can chemotherapy delivered directly to the affected area offer better results for patients?

That is the central question driving IMPACT's research.

Aerosolised drug delivery is already used in some specialist cancer centres. But important questions remain about how well it works, how safe it is and which patients might benefit most.

IMPACT is designed to address those gaps through three randomised clinical trials comparing treatment approaches in patients with cancers affecting the abdomen or chest.

The research will examine not only clinical outcomes but also whether the treatment improves patients' symptoms and everyday lives.

Aerosolised drug delivery

Chemotherapy as a fine aerosol, delivered into the abdominal or pleural cavity rather than only through the bloodstream.

Three clinical trials

Effectiveness, safety and quality of life in colorectal cancer, gastric cancer and malignant pleural effusion.

PIPAC, PITAC and ESP

The techniques IMPACT will evaluate: pressurised aerosol delivery in the abdomen and chest, and electrostatic precipitation.

Clinical programme

Three randomised trials

Each of them investigates a different clinical setting, helping researchers understand where aerosolised chemotherapy could make a meaningful difference.

Techniques

PIPAC, PITAC and electrostatic precipitation

The clinical techniques and delivery technology that IMPACT will evaluate.

PIPAC

Pressurised Intraperitoneal Aerosol Chemotherapy delivers chemotherapy as a pressurised aerosol into the abdominal cavity during a minimally invasive procedure.

PITAC

Pressurised Intrathoracic Aerosol Chemotherapy applies the same principle in the chest, delivering aerosolised chemotherapy into the pleural cavity.

ESP

Electrostatic precipitation uses an electric field to help aerosolised treatment deposit more effectively into tumour tissue.

Patients

Patient and quality-of-life

For someone living with advanced cancer, the impact of treatment extends far beyond what appears on a scan.

Can they breathe more easily? Are their symptoms less severe? Can they manage everyday activities? How does treatment affect their physical and emotional wellbeing?

These questions are central to IMPACT.

Measuring what matters to patients

Alongside clinical outcomes, researchers will assess symptoms, quality of life and patients' own reports of how they feel and function during treatment.

This will help build a fuller picture of the potential benefits and burdens of aerosolised chemotherapy.

Patient involvement

Patients, relatives and caregivers will contribute throughout the project.

Through a Patient Advisory Board and wider consultation, they will help shape trial protocols, patient information, outcome measures and communication.

Their involvement will help ensure the research addresses the questions and concerns that matter most to people affected by cancer.

Health systems

From research to routine care

Is it worth the investment?

IMPACT wants to investigate just that, evaluating the cost-effectiveness of aerosolised drug delivery compared with standard care and examining. what would be required for its introduction across different European healthcare systems. This includes implementation strategies and practical tools to support future decision-making.

Health technology assessment

HTA is the systematic assessment of the clinical, economic and wider value of a healthcare intervention. IMPACT will use it to examine cost-effectiveness across European healthcare systems.

Turning research into practice

The project will develop and test practical implementation strategies and tools to help healthcare providers assess whether, and how, aerosolised chemotherapy could become part of routine cancer care.

The aim is to ensure that, if the trials demonstrate sufficient benefits, hospitals and healthcare systems have the information they need to act on the findings.